| scholarly article | Q13442814 |
| P50 | author | Howard L. Weiner | Q20985921 |
| Tanuja Chitnis | Q30353265 | ||
| P2093 | author name string | Rohit Bakshi | |
| Brian C Healy | |||
| Shahamat Tauhid | |||
| Muhammad T Malik | |||
| Sheena L Dupuy | |||
| Alicia S Chua | |||
| Camilo Diaz-Cruz | |||
| Vinit V Oommen | |||
| P2860 | cites work | Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS) | Q22241644 |
| Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” | Q22252938 | ||
| The effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysis | Q26824991 | ||
| A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis | Q28270998 | ||
| Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis | Q28271008 | ||
| Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial | Q30789784 | ||
| Role of MRI in multiple sclerosis I: inflammation and lesions | Q30892336 | ||
| The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force | Q33722674 | ||
| Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis | Q34624835 | ||
| New management algorithms in multiple sclerosis | Q38206631 | ||
| FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease. | Q39049796 | ||
| FTY720 attenuates excitotoxicity and neuroinflammation. | Q40613316 | ||
| Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". | Q43721330 | ||
| Effect of natalizumab on conversion of gadolinium enhancing lesions to T1 hypointense lesions in relapsing multiple sclerosis | Q47767879 | ||
| Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations | Q48770400 | ||
| Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis | Q48851784 | ||
| P433 | issue | 2 | |
| P921 | main subject | multiple sclerosis | Q8277 |
| P304 | page(s) | 184-187 | |
| P577 | publication date | 2015-10-08 | |
| P1433 | published in | Journal of Neuroimaging | Q15765423 |
| P1476 | title | The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis | |
| P478 | volume | 26 |
| Q48343851 | Association Between Serum MicroRNAs and Magnetic Resonance Imaging Measures of Multiple Sclerosis Severity |
| Q26765300 | Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations |
| Q38606914 | Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosis |
| Q89938771 | Magnetic Resonance Imaging in Multiple Sclerosis |
| Q90625135 | Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis |
| Q42339266 | Peginterferon beta-1a reduces the evolution of MRI lesions to black holes in patients with RRMS: a post hoc analysis from the ADVANCE study |
| Q38859250 | Tracking the Evolution of Cerebral Gadolinium-Enhancing Lesions to Persistent T1 Black Holes in Multiple Sclerosis: Validation of a Semiautomated Pipeline. |
Search more.